Swiss pharma warns 100% tariffs

Pharmaceutical tariffs are now a live policy, not just a Trump threat. On April 2, the White House rolled out a new regime for imported patented drugs and their ingredients, and a day later Switzerland’s industry group Interpharma fired back. The basic warning was simple — if you make global medicine supply more expensive and more political, patients get hit. But the actual policy is more complicated than the scary 100% headline. ### What did Trump actually do? Trump’s April 2 order used Section 232 national-security authority to impose tariffs on patented pharmaceutical products and ingredients. The headline rate was 100%, and that is the number that grabbed everyone’s attention. But the order also built in different country rates, exemptions, and off-ramps for companies willing to cut U.S. prices or move manufacturing into the United States. (whitehouse.gov) ### Is Switzerland really facing 100%? Not in the clean, across-the-board way the first headlines suggested. The White House fact sheet says products from the EU, Japan, Korea, Switzerland, and Liechtenstein face a 15% tariff tier, not 100%. The 100% rate is aimed at patented drugs and ingredients that do not fit into those trade-deal arrangements or company-level compliance paths. That distinction matters a lot, because it means the policy is both punitive and negotiable. (whitehouse.gov) ### So why is Interpharma alarmed? Because even a 15% tariff on a cross-border drug supply chain is a big deal, and the policy can tighten fast. Interpharma said the U.S. move threatens global production, supply chains, research and development, and ultimately patients. T(whitehouse.gov)the cost ripples outward. (finance.yahoo.com) ### What is the U.S. trying to force? Two things at once — more domestic manufacturing and lower drug prices. The administration created a menu. Companies that sign both U.S. onshoring agreements and “most favored nation” pricing deals can get a 0% tariff through January 20, 2029. Companies that only commit to onshoring can get a 20% tariff instead of 100%. Bigger drugmakers have 120 days before the top rate kicks in, while smaller ones get 180 days. (whitehouse.gov) ### Which drugs are spared? Generics and biosimilars are not covered right now. Orphan drugs, animal-health products, and some specialty medicines can also be exempt, especially from trade-deal countries or where there is an urgent public-health need. That narrows the immediate blast radius. But it also means the pressure is concentrated on the branded, patented medicines that make the most money and anchor a lot of Swiss pharma exports. (whitehouse.gov) ### Why does Switzerland care so much? Because pharma is not some side industry there — it is the core export machine. Chemical and pharmaceutical products made up more than half of Switzerland’s total exports in 2025, and Swiss exports to the U.S. were worth 54.7 billion Swiss francs once gold and similar categories are stripped out. When Washington leans on imported branded drugs, Switzerland is one of the countries standing closest to the blast zone. (finance.yahoo.com) ### Why mention Britain? Interpharma wants Bern to copy the UK playbook. Britain secured tariff-free access for UK-made medicines under a separate arrangement, and Interpharma explicitly pointed to that deal as the model Switzerland should chase. Basically, the Swiss industry is saying this is no longer just a trade dispute — it is a bilateral negotiation where favored countries can still carve out better terms. (finance.yahoo.com) ### What is the bottom line? The real story is not “Swiss drugs got hit with 100% tariffs.” It is that Trump built a coercive tariff system around patented medicines, Switzerland still got caught in it, and Swiss pharma is warning that even the softened version can scramble supply chains and patient access. The catch is that the pain is also the point — Washington wants drugmakers to reshuffle where they make medicines and how much they charge in the U.S. (whitehouse.gov)